Abstract: Hepatitis C virus inhibitors having the general formula (I) are disclosed. Compositions comprising the compounds and methods for using the compounds to inhibit HCV are also disclosed.
Type:
Grant
Filed:
October 28, 2013
Date of Patent:
May 9, 2017
Assignee:
Bristol-Myers Squibb Company
Inventors:
Li-Qiang Sun, Qian Zhao, Kishore V. Renduchintala, Kandhasamy Sarkunam, Pulicharla Nagalakshmi, Eric P. Gillis, Paul Michael Scola
Abstract: This invention is directed to a method of treating Excessive daytime Sleepiness (EDS) in a subject, comprising the step of administering a therapeutically effective amount of a compound of Formula (I): Formula (I) or a pharmaceutically acceptable salt or ester thereof wherein Rx is a member selected from the group consisting of hydrogen, lower alkyl of 1 to 8 carbon atoms, halogen selected from F, Cl, Br and I, alkoxy containing 1 to 3 carbon atoms, nitro, hydroxy, trifluoromethyl, and thioalkoxy containing 1 to 3 carbon atoms; x is an integer of 1 to 3, with the proviso that R may be the same or different when x is 2 or 3; R1 and R2 can be the same or different from each other and are independently selected from the group consisting of hydrogen, lower alkyl of 1 to 8 carbon atoms, aryl, arylalkyl, cycloalkyl of 3 to 7 carbon atoms; R1 and R2 can be joined to form a 5 to 7-membered heterocycle substituted with a member selected from the group consisting of hydrogen, alkyl, and aryl groups, wherein the cyclic
Type:
Grant
Filed:
August 6, 2014
Date of Patent:
March 28, 2017
Assignee:
SK Biopharmaceuticals Co., Ltd.
Inventors:
Abdallah Ahnaou, Wilhelmus H. I. M. Drinkenburg, Joseph Palumbo, Jonathan Sporn
Abstract: Provided herein are substituted biaryl sulfonamide compounds, pharmaceutical compositions comprising the compounds, methods of their preparation, and methods of their use. The compounds provided herein are useful for the treatment, prevention, and/or amelioration of various disorders, including cancer and proliferative disorders. In one embodiment, the compounds provided herein modulate initiation of protein translation. In one embodiment, the compounds provided herein are used in combination with surgery, radiation therapy, immuno therapy and/or one or more additional anticancer drugs for the treatment, prevention, and/or amelioration of cancer and proliferative disorders.
Type:
Grant
Filed:
September 30, 2015
Date of Patent:
March 28, 2017
Assignee:
NovoMedix, LLC
Inventors:
Leah M. Fung, Kyle W. H. Chan, Cathy A. Swindlehurst, Robert W. Sullivan
Abstract: The invention provides a method of inhibiting the effects of platelet activating factor (PAF). For instance, a disease or condition mediated by PAF (particularly inflammation) can be treated or platelet aggregation can be inhibited. The invention also provides a method of inhibiting the production and/or release of interleukin 8 (IL-8) by cells. The effects of PAF and the production and/or release of IL-8 are inhibited according to the invention by a compound of the formula: wherein R1 and R2 are defined in the application, or a physiologically-acceptable salt thereof. The invention also provides pharmaceutical compositions comprising these compounds.
Type:
Grant
Filed:
August 8, 2014
Date of Patent:
February 7, 2017
Assignee:
Ampio Pharmaceuticals, Inc.
Inventors:
David Bar-Or, C. Gerald Curtis, Nagaraja K. R. Rao, Greg Thomas
Abstract: The invention provides compounds of formula I: wherein A, B, X, and Y have any of the values defined in the specification, as well as pharmaceutical compositions comprising such compounds, processes for preparing such compounds, and therapeutic methods for treating cancer and other topoisomerase mediated conditions.
Type:
Grant
Filed:
March 5, 2010
Date of Patent:
February 7, 2017
Assignee:
Rutgers, the State University of New Jersey
Inventors:
Edmond J. LaVoie, Wei Feng, Leroy F. Liu
Abstract: The present disclosure relates to compounds, compositions and methods for the treatment of Hepatitis C virus (HCV) infection. Also disclosed are pharmaceutical compositions containing such compounds and methods for using these compounds in the treatment of HCV infection.
Type:
Grant
Filed:
May 7, 2012
Date of Patent:
January 17, 2017
Assignee:
Bristol-Myers Squibb Company
Inventors:
Qi Chen, Omar D. Lopez, John A. Bender, Gan Wang, Van N. Nguyen, John F. Kadow, Nicholas A. Meanwell, Makonen Belema
Abstract: Disclosed are formulations of gamma-hydroxybutyrate in an aqueous medium that are resistant to microbial growth. Also disclosed are formulations of gammahydroxybutyrate that are also resistant to the conversion into GBL. Disclosed are methods to treat sleep disorders, including narcolepsy, with these stable formulations of GHB. The present invention also provides methods to treat alcohol and opiate withdrawal, reduced levels of growth hormone, increased intracranial pressure, and physical pain in a patient.
Type:
Grant
Filed:
November 9, 2015
Date of Patent:
January 10, 2017
Assignee:
Jazz Pharmaceuticals, Inc.
Inventors:
Harry Cook, Martha Hamilton, Douglas Danielson, Colette Goderstad, Dayton T. Reardan
Abstract: Hepatitis C virus inhibitors having the general formula (I) are disclosed. Compositions comprising the compounds and methods for using the compounds to inhibit HCV are also disclosed.
Type:
Grant
Filed:
January 8, 2015
Date of Patent:
December 27, 2016
Assignee:
Bristol-Myers Squibb Company
Inventors:
Sheldon Hiebert, Ramkumar Rajamani, Li-Qiang Sun, Eric Mull, Eric P. Gillis, Michael S. Bowsher, Qian Zhao, Nicholas A. Meanwell, Kishore V. Renduchintala, Kandhasamy Sarkunam, Pulicharla Nagalakshmi, P.V.K. Suresh Babu, Paul Michael Scola
Abstract: The present invention relates to Fibroblast Growth Factor 21 (FGF21), more in particular to derivatives of FGF21 compounds having an albumin binder of the formula A-B-C-D-E- covalently attached. The invention also relates to novel FGF21 analogues, as well as to the pharmaceutical use of these FGF21 derivatives and analogues, in particular for the treatment of diabetes, dyslipidemia, obesity, cardiovascular diseases, metabolic syndrome, and/or Non Alcoholic Fatty Liver Disease (NAFLD). The derivatives of the invention are protracted, e.g. capable of maintaining a low blood glucose level for a longer period of time, capable of increasing the in vivo half-life of FGF21, and/or result in a lower clearance of FGF21. The derivatives of the invention are preferably furthermore of an improved oxidative stability.
Type:
Grant
Filed:
January 22, 2010
Date of Patent:
November 1, 2016
Assignee:
Novo Nordisk A/S
Inventors:
Tina Møller Tagmose, Patrick William Garibay, Bírgítte Andersen, Henning Thøgersen, Birgit Wieczorek
Abstract: The invention provides a latanoprost-containing aqueous pharmaceutical composition filled in a filter-equipped container, with the adsorption of latanoprost by the filter being prevented. In the latanoprost-containing aqueous pharmaceutical composition filled in the filter-equipped container, a nonionic surfactant is contained in the composition and the filter is made from at least one material selected from the group consisting of polyether sulfone, polyvinylidene fluoride, polycarbonate, and polytetrafluoroethylene.
Abstract: Disclosed is a method of treating a cancer on a mammal, comprising administering to the mammal in need thereof a therapeutically effective amount of a compound
Type:
Grant
Filed:
November 12, 2012
Date of Patent:
August 9, 2016
Assignee:
MITOTECH S.A.
Inventors:
Vladimir P. Skulachev, Maxim V. Skulachev
Abstract: The invention encompasses a compound derived from hydroxamic acid that may be used to slow the expansion of cancer cells and thus is effective in the treatment of cancer. Generally, the disclosed compound includes a benzimidazole group coupled to a hydroxyamide of five or more unsubstituted carbon atoms and any pharmaceutically acceptable salts, solvates and chemically protected forms thereof. Also disclosed are pharmacological compositions including the compound and methods of using the compound to slow the expansion of cancer cells as well as methods of using the compound to treat cancer.
Type:
Grant
Filed:
March 19, 2015
Date of Patent:
July 5, 2016
Assignee:
The Translational Genomics Research Institute
Abstract: The invention provides compounds according to formula (I): (wherein X, Y, Z1 R1, R2, R3, Ar and Ar? are as defined herein), and physiologically acceptable salts, solvates, esters or amides thereof, pharmaceutical compositions comprising these compounds and the compounds for use in medicine, for example for the treatment or prophylaxis of diseases involving cell proliferation, such as cancer, and for the treatment or prophylaxis of other diseases.
Type:
Grant
Filed:
June 9, 2010
Date of Patent:
June 14, 2016
Assignees:
University Court of the University of St Andrews, University Court of the University of Dundee
Inventors:
Sonia Lain, Nicholas James Westwood, David Philip Lane
Abstract: The present invention relates to substituted aminoquinoxaline compounds of general formula (I) in which (II), R2, R3, R4, R6, R7, n and m are as given in the description and in the claims, to methods of preparing said compounds, to pharmaceutical compositions and combinations comprising said compounds, to the use of said compounds for manufacturing a pharmaceutical composition for the treatment or prophylaxis of a disease, as well as to intermediate compounds useful in the preparation of said compounds.
Type:
Grant
Filed:
August 24, 2010
Date of Patent:
May 17, 2016
Assignee:
BAYER PHARMA AKTIENGESELLSCHAFT
Inventors:
Benjamin Bader, Ulf Bömer, Stuart Ince, Marcus Koppitz, Philip Lienau, Tobias Marquardt, Duy Nguyen, Stefan Prechtl, Gerhard Siemeister, Christof Wegscheid-Gerlach
Abstract: The present invention provides compounds of Formula (I) that are useful for modulating the biological activity of the melanocortin-5 receptor (MC5R). Compounds of this invention can be used to treat diseases and/or conditions in which downregulation of MC5R is beneficial. Such diseases and/or conditions include, but are not limited to, acne, seborrhea, seborrheic dermatitis, cancer, and inflammatory diseases.
Type:
Grant
Filed:
January 9, 2013
Date of Patent:
May 17, 2016
Assignee:
Mimetica PTY LTD
Inventors:
Mark Arnold Thomas Blaskovich, Peter Joseph Cassidy
Abstract: Esters of 2-propylheptanol with linear or branched, saturated or unsaturated C5-C36 carboxylic acids and C4-C36 dicarboxylic acids, compositions comprising these esters, and to the use of esters of 2-propylheptanol with linear or branched, saturated or unsaturated C5-C36-carboxylic acids and/or C4-C36-dicarboxylic acids in cosmetic and/or topical pharmaceutical preparations.
Type:
Grant
Filed:
January 7, 2014
Date of Patent:
April 19, 2016
Assignee:
Cognis IP Management GmbH
Inventors:
Markus Dierker, Catherine Weichold, Stefanie Althaus, Lars Zander, Daniela Prinz
Abstract: Esters of 2-propylheptanol with linear or branched, saturated or unsaturated C5-C36 carboxylic acids and C4-C36 dicarboxylic acids, compositions comprising these esters, and to the use of esters of 2-propylheptanol with linear or branched, saturated or unsaturated C5-C35-carboxylic acids and/or C4-C36-dicarboxylic acids in cosmetic and/or topical pharmaceutical preparations.
Type:
Grant
Filed:
January 7, 2014
Date of Patent:
April 19, 2016
Assignee:
Cognis IP Management GmbH
Inventors:
Markus Dierker, Catherine Weichold, Stefanie Althaus, Lars Zander, Daniela Prinz
Abstract: The present invention provides compounds, pharmaceutically acceptable compositions thereof, and methods of using the same.
Type:
Grant
Filed:
April 6, 2012
Date of Patent:
April 5, 2016
Assignee:
Sloan-Kettering Institute for Cancer Research
Inventors:
Samuel J. Danishefsky, Joan Massague, Manuel Valiente Cortes, Thordur Oskarsson, Malcom Moore, Nicolas Lecomte, Ouathek Ouerfelli, Guangli Yang
Abstract: Pro-apoptotic compounds having a tripartite structure: A-L-B are disclosed. In these compounds A is an IBM mimetic moiety; L is a linker and B is a moiety that binds to a protein on the outer mitochondrial membrane. The compounds are useful for inducing cell apoptosis and therefore treating cancer.
Type:
Grant
Filed:
September 12, 2012
Date of Patent:
December 15, 2015
Assignee:
The Rockefeller University
Inventors:
Hermann Steller, Cristinel Sandu, Anshuman Kelkar, Nidhi Gangadhar